Mazdutide vs Survodutide
A side-by-side research comparison of Mazdutide and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Mazdutide | Survodutide |
|---|---|---|
| Full name | Mazdutide (Dual GLP-1/Glucagon Agonist) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Dual activation of GLP-1 receptors for appetite suppression combined with glucagon receptor activation for enhanced hepatic lipid oxidation and energy expenditure. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 4,300 Da (approximate) | 4,500 Da (approximate) |
| Half-life | 5-7 days | 5-7 days |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 3-9 mg | 0.6-6.0 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous | Subcutaneous |
Mazdutide reported benefits
- Significant weight loss (up to 18%)
- Liver fat reduction
- Improved insulin sensitivity
- Once-weekly convenience
- Potential MASH benefit
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.